RVMD Revolution Medicines Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RVMD

Price (delayed)

$23.33

Market cap

$2.56B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.24

Enterprise value

$2.26B

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities ...

Highlights
The debt has contracted by 3.6% YoY
The company's equity rose by 23% YoY but it fell by 10% QoQ
RVMD's quick ratio is down by 19% since the previous quarter but it is up by 6% year-on-year
Revolution Medicines's net income has decreased by 35% YoY and by 12% from the previous quarter
The gross profit has declined by 11% since the previous quarter and by 11% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://revolutionmedicines.com
Peers: OMGA

Key stats

What are the main financial stats of RVMD
Market
Shares outstanding
109.56M
Market cap
$2.56B
Enterprise value
$2.26B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
97.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.3
Earnings
Revenue
$26.17M
EBIT
-$335.33M
EBITDA
-$326.28M
Free cash flow
-$300.09M
Per share
EPS
-$3.24
Free cash flow per share
-$2.75
Book value per share
$7.67
Revenue per share
$0.24
TBVPS
$8.35
Balance sheet
Total assets
$984.23M
Total liabilities
$146.77M
Debt
$62.85M
Equity
$837.46M
Working capital
$738.93M
Liquidity
Debt to equity
0.08
Current ratio
9.64
Quick ratio
9.54
Net debt/EBITDA
0.91
Margins
EBITDA margin
-1,246.9%
Gross margin
100%
Net margin
-1,266.2%
Operating margin
-1,409.8%
Efficiency
Return on assets
-33.6%
Return on equity
-38.9%
Return on invested capital
-58.6%
Return on capital employed
-37.3%
Return on sales
-1,281.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

RVMD stock price

How has the Revolution Medicines stock price performed over time
Intraday
3.87%
1 week
8.82%
1 month
27.14%
1 year
-1.1%
YTD
-2.06%
QTD
-15.72%

Financial performance

How have Revolution Medicines's revenue and profit performed over time
Revenue
$26.17M
Gross profit
$26.17M
Operating income
-$368.91M
Net income
-$331.34M
Gross margin
100%
Net margin
-1,266.2%
Revolution Medicines's operating margin has plunged by 67% YoY and by 29% from the previous quarter
The net margin has plunged by 53% YoY and by 26% from the previous quarter
RVMD's operating income is down by 48% year-on-year and by 14% since the previous quarter
Revolution Medicines's net income has decreased by 35% YoY and by 12% from the previous quarter

Growth

What is Revolution Medicines's growth rate over time

Valuation

What is Revolution Medicines stock price valuation
P/E
N/A
P/B
3.04
P/S
97.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
86.3
The EPS has declined by 3.8% since the previous quarter
The company's equity rose by 23% YoY but it fell by 10% QoQ
The stock's price to sales (P/S) is 20% more than its last 4 quarters average of 81.4
The revenue has declined by 11% since the previous quarter and by 11% year-on-year

Efficiency

How efficient is Revolution Medicines business performance
The return on sales has dropped by 54% year-on-year and by 28% since the previous quarter
RVMD's ROIC is down by 25% year-on-year and by 15% since the previous quarter
RVMD's ROA is down by 7% QoQ
Revolution Medicines's return on equity has increased by 7% YoY but it has decreased by 7% QoQ

Dividends

What is RVMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RVMD.

Financial health

How did Revolution Medicines financials performed over time
RVMD's total assets is up by 19% year-on-year but it is down by 8% since the previous quarter
RVMD's quick ratio is down by 19% since the previous quarter but it is up by 6% year-on-year
The debt is 92% less than the equity
The company's equity rose by 23% YoY but it fell by 10% QoQ
The debt to equity has contracted by 20% YoY but it has grown by 14% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.